Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2026-03-25 00:00:00 ET · period of report 2026-03-23 · accession 0001193125-26-124367 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-03-25 | 2026-03-23+ | KYMR | Chadwick Jeremy G | COO | M - OptEx | $29.64 | +109.1K | 152.5K | +252% | +$3.23M |
| DMT | 2026-03-25 | 2026-03-23+ | KYMR | Chadwick Jeremy G | COO | S - Sale+OE | $78.02 | -116.0K | 61.2K | -65% | -$9.05M |
| DMT | 2026-03-25 | 2026-03-23+ | KYMR | Chadwick Jeremy G | COO | M - OptEx | $0.00 | -109.1K | 90.9K | -55% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-25 | M | A | 24,727 | $29.64 | 85,929 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-25 | S | D | 24,727 | $80.26 | 61,202 | D | — | — | (F6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-03-23 | M | A | 84,400 | $29.64 | 152,452 | D | — | — | |
| 4 | Common | Common Stock | 2026-03-23 | S | D | 6,105 | $79.87 | 62,402 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.01 to $80.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2026-03-23 | S | D | 8,214 | $78.40 | 68,507 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.98 to $78.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2026-03-23 | S | D | 52,975 | $77.21 | 76,721 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.95 to $77.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Common | Common Stock | 2026-03-23 | S | D | 22,756 | $76.73 | 129,696 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.96 to $76,94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 8 | Common | Common Stock | 2026-03-23 | S | D | 1,200 | $80.05 | 61,202 | D | — | — | |
| 9 | Derivative | Stock Option (Right to Buy) | 2026-03-23 | M | D | 84,400 | $0.00 | 115,600 | D | $29.64 · — to 2033-05-22 | 84,400 Common Stock | (F7) Twenty-five percent (25%) of the shares underlying this stock option vested on May 22, 2024 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. |
| 10 | Derivative | Stock Option (Right to Buy) | 2026-03-25 | M | D | 24,727 | $0.00 | 90,873 | D | $29.64 · — to 2033-05-22 | 24,727 Common Stock | (F7) Twenty-five percent (25%) of the shares underlying this stock option vested on May 22, 2024 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. |